2015-05-28 13:53:46 UTC

FDA Approves New IBS-D Therapies

May 28, 2015

Two new treatments have received FDA approval to treat adults with diarrhea-predominant IBS.

The FDA has approved two new treatments for IBS with diarrhea in adult men and women — Viberzi (eluxadoline) and Xifaxan (rifaximin). The products are manufactured by two different companies.

Viberzi, which contains a new active ingredient, is taken orally twice daily with food. Viberzi activates receptors in the nervous system that can lessen bowel contractions. Viberzi is intended to treat adults with IBS-D.

Xifaxan can be taken orally three times a day for 14 days, for the treatment of abdominal pain and diarrhea in patients with IBS-D. Patients who experience a recurrence of symptoms can be retreated with a 14-day treatment course, up to two times. Xifaxan, an antibiotic derived from rifampin, was previously approved as treatment for travelers’ diarrhea caused-by E. coli and for reducing the risk of recurring overt hepatic encephalopathy, the changes in brain function that occur when the liver is unable to remove toxins from the blood. The exact mechanism of action of Xifaxan for treatment of IBS-D is not known, but is thought to be related to changes in the bacterial content of the gastrointestinal tract.

More on Irritable Bowel Syndrome

Help Ease the Frustrations of Your IBS Patients

Oct. 18, 2017

Resources are available to help you provide an overview of symptoms, testing and the best treatment options for your patients.

Blog: Can a Diet Low in FODMAPs Reduce IBS Symptoms in the Real World?

Oct. 18, 2017

New research shows low-FODMAP diet more efficacious than a sham diet with patients indicating a better quality of life. Read more on the AGA Journals blog.

A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial

Oct. 1, 2017

Low FODMAP dietary advice leads to improved IBS symptoms compared with placebo dietary advice. Consumption of a multistrain probiotic with a low FODMAP diet could help to restore the Bifidobacteria species in the gut.